The VICI Venous Stent System (Boston Scientific) is associated with excellent primary patency rates, with concomitant symptomatic improvement in Clinical-Etiological-Anatomical-Pathophysiological (CEAP) classification, directly after stenting and in long-term follow-up out to 36 months. This is the headline finding of a subgroup analysis from the Arnsberg Venous registry, recently presented by one of the principal investigators, Michael Lichtenberg (Karolinen Hospital, Arnsberg, Germany) at LINC 2021 (Leipzig Interventional Course; 25–29 January, virtual). These long-term data add to a growing body of clinical evidence in support of the VICI Venous Stent System, and make it the only dedicated venous stent with data out to three years—a crucial edge in a growing field.
